NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

XGN

Exagen Inc

Jul 03 • 02:54PM ET

7.05

Dollar change +0.08
Percentage change 1.15	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN ONC MYGN QGEN NTRA GH VCYT CDNA PRPO FLGT

| Held by: VTI VXF IWC QQQS DFAC DFSU DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.84	Insider Own	38.53%	Shs Outstand	17.95M	Perf Week	0.86%
Market Cap	154.12M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	-3.99%	Shs Float	13.44M	Perf Month	-4.60%
Enterprise Value	166.37M	PEG	-	EPS next Q	-0.15	Inst Own	28.53%	Short Float	1.52%	Perf Quarter	59.14%
Income	-15.51M	P/S	2.72	EPS this Y	31.22%	Inst Trans	-2.91%	Short Ratio	0.85	Perf Half Y	64.72%
Sales	56.72M	P/B	19.76	EPS next Y	55.19%	ROA	-34.04%	Short Interest	0.20M	Perf YTD	71.95%
Book/sh	0.36	P/C	13.77	EPS next 5Y	49.02%	ROE	-117.50%	52W High	7.95 -11.32%	Perf Year	289.50%
Cash/sh	0.51	P/FCF	-	EPS past 3/5Y	20.95% 19.20%	ROIC	-59.24%	52W Low	1.71 312.28%	Perf 3Y	29.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.83% 6.62%	Gross Margin	59.30%	Volatility	4.58% 6.30%	Perf 5Y	-35.91%
Dividend TTM	-	EV/Sales	2.93	EPS Y/Y TTM	22.46%	Oper. Margin	-24.68%	ATR (14)	0.46	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.98	Sales Y/Y TTM	1.78%	Profit Margin	-27.34%	RSI (14)	53.32	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	2.32	EPS Q/Q	-8.01%	SMA20	-1.31%	Beta	1.61	Target Price	7.75
Payout	-	Debt/Eq	3.66	Sales Q/Q	7.51%	SMA50	5.87%	Rel Volume	0.94	Prev Close	6.97
Employees	209	LT Debt/Eq	3.09	Earnings	May 05 BMO	SMA200	58.83%	Avg Volume	240.72K	Price	7.05
IPO	Sep 19, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.09% 6.55%	Trades		Volume	227,319	Change	1.15%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Oct-15-21	Resumed	Cowen	Outperform	$26
Apr-15-21	Initiated	Canaccord Genuity	Buy	$25
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$32
Oct-08-20	Initiated	BTIG Research	Buy	$18
Jun-02-20	Resumed	Cantor Fitzgerald	Overweight	$19 → $20
Oct-14-19	Initiated	William Blair	Outperform
Oct-14-19	Initiated	Cowen	Outperform	$17
Oct-14-19	Initiated	Cantor Fitzgerald	Overweight	$18

Jun-23-25 09:00AM	Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics (GlobeNewswire)
May-09-25 04:05PM	Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares (GlobeNewswire) -7.31%
May-08-25 08:30AM	Exagen Inc. Prices Public Offering of Common Stock (GlobeNewswire) -9.81%
May-07-25 04:05PM	Exagen Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +6.39%
May-06-25 03:03AM	Exagen Inc (XGN) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Wins Amidst ... (GuruFocus.com)
01:18AM	Loading…
01:18AM	Q1 2025 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 04:51PM	Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume (GlobeNewswire)
May-02-25 09:36AM	Exagen Inc (XGN) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-28-25 09:00AM	Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors (GlobeNewswire) +7.09%
Apr-26-25 03:31AM	Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability (Seeking Alpha)
Apr-21-25 04:05PM	Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire) +9.26%
Mar-12-25 03:04AM	Exagen Inc (XGN) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives (GuruFocus.com)
12:10AM	Q4 2024 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
09:15AM	Loading…
Mar-11-25 09:15AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +18.25%
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights (GlobeNewswire)
Feb-25-25 04:05PM	Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025 (GlobeNewswire)
Feb-05-25 06:38AM	Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength? (Zacks) +6.18%
Feb-04-25 04:05PM	Exagen Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire) +29.38%
Jan-12-25 12:00PM	Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results (GlobeNewswire)
Dec-12-24 09:00AM	Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE CTD (GlobeNewswire) +12.02%
Nov-14-24 04:30PM	Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE CTD Platform (GlobeNewswire) +5.45%
Nov-13-24 04:05PM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
02:09AM	Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... (GuruFocus.com)
12:51AM	Q3 2024 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 09:25AM	Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.06%
Nov-11-24 07:25AM	Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:05PM	Exagen to Announce Third Quarter 2024 Results on November 12, 2024 (GlobeNewswire)
Oct-21-24 04:05PM	Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence (GlobeNewswire)
04:05PM	Loading…
Sep-04-24 04:05PM	Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire) +15.93%
Aug-29-24 09:55AM	Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now (Zacks)
Aug-26-24 08:50AM	Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Aug-09-24 09:15AM	Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? (Zacks) +22.46%
Aug-08-24 08:50AM	Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain (Zacks) +12.65%
Aug-05-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +17.65%
09:10AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance (GlobeNewswire)
Aug-02-24 09:00AM	Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 09:00AM	Exagen Appoints Jeffrey G. Black as New Chief Financial Officer (GlobeNewswire)
Jul-22-24 09:00AM	Exagen to Announce Second Quarter 2024 Results on August 5, 2024 (GlobeNewswire)
Jun-13-24 08:50AM	Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors (Zacks)
May-15-24 05:01AM	Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ... (GuruFocus.com) +8.52%
May-13-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year (GlobeNewswire)
May-06-24 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-30-24 04:05PM	Exagen to Announce First Quarter 2024 Results on May 13, 2024 (GlobeNewswire)
Apr-26-24 08:30AM	Exagen Inc. Announces Changes to the Board of Directors (GlobeNewswire)
Mar-19-24 09:37AM	Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript (Insider Monkey) -12.99%
01:55AM	Q4 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 12:52PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +9.26%
09:25AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Mar-08-24 09:00AM	Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire)
Mar-07-24 04:05PM	Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 (GlobeNewswire)
Feb-06-24 08:50AM	Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock (Zacks)
Jan-30-24 04:05PM	Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire) -6.52%
Jan-07-24 12:00PM	Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance (GlobeNewswire)
Nov-13-23 04:05PM	Exagen Inc. Reports Strong Third Quarter 2023 Results (GlobeNewswire) +16.44%
Nov-09-23 04:05PM	Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers (GlobeNewswire) -6.25%
Nov-02-23 04:05PM	Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Oct-30-23 04:05PM	Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023 (GlobeNewswire) +6.75% +6.08%
Sep-28-23 04:05PM	Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting (GlobeNewswire)
Sep-12-23 04:05PM	Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-09-23 10:47AM	Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call Transcript (Insider Monkey) -7.22%
Aug-08-23 04:13AM	Q2 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 09:15AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.76%
08:00AM	Exagen Inc. Reports Strong Second Quarter 2023 Results (GlobeNewswire)
Jul-26-23 04:05PM	Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-25-23 04:05PM	Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire) -6.51%
Jul-24-23 04:05PM	Exagen Inc. Appoints Paul Kim to Board of Directors (GlobeNewswire)
07:33AM	This Exagen Insider Increased Their Holding In The Last Year (Simply Wall St.)
Jun-13-23 08:19AM	Exagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For Excitement (Simply Wall St.) -8.36%
May-30-23 09:00AM	Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference (GlobeNewswire)
May-17-23 07:11AM	Exagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three years (Simply Wall St.) -6.90%
May-16-23 11:03AM	Q1 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents) +19.51%
May-15-23 05:55PM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Exagen Inc. Reports First Quarter 2023 Results (GlobeNewswire)
May-01-23 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-24-23 04:05PM	Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire)
Mar-24-23 08:16AM	Exagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 06:12AM	Exagen Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Mar-21-23 07:40AM	Q4 2022 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-23 05:25PM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
Mar-06-23 04:05PM	Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023 (GlobeNewswire) +5.31%
Feb-27-23 09:00AM	Exagen Inc. to Participate in Upcoming March Conferences (GlobeNewswire)
Feb-14-23 06:19AM	Exagen Inc. (NASDAQ:XGN) insider upped their holding earlier this year (Simply Wall St.)
Jan-30-23 04:05PM	Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Jan-23-23 09:00AM	Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors (GlobeNewswire)
Nov-14-22 07:55PM	Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.49% +42.38%
04:05PM	Exagen Inc. Reports Third Quarter 2022 Results (GlobeNewswire)
Nov-08-22 04:05PM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
Oct-31-22 04:05PM	Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Oct-17-22 09:00AM	Exagen Announces Appointment of John Aballi as CEO (GlobeNewswire)
Oct-04-22 08:25AM	Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer (GlobeNewswire)
Sep-20-22 04:05PM	Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting (GlobeNewswire) -10.02%
Sep-19-22 10:20AM	The past three years for Exagen (NASDAQ:XGN) investors has not been profitable (Simply Wall St.) -8.67%
Sep-01-22 04:05PM	Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients (GlobeNewswire)

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NMSIC Co-Investment Fund, L.P.	10% Owner	Mar 25 '25	Sale	3.30	350,000	1,155,000	1,758,958	Mar 27 04:15 PM
NMSIC Co-Investment Fund, L.P.	10% Owner	Nov 20 '24	Sale	3.30	200,000	660,040	2,108,958	Nov 27 04:18 PM
Black Jeffrey G.	Chief Financial Officer	Nov 15 '24	Buy	2.98	22,298	66,448	274,492	Nov 19 07:24 PM
ABALLI JOHN	President and CEO	Nov 14 '24	Buy	2.81	24,305	68,297	689,799	Nov 18 06:32 PM
Adawi Kamal	Officer	Oct 08 '24	Proposed Sale	2.94	84,162	247,436		Oct 08 04:39 PM
Adawi Kamal	Officer	Aug 09 '24	Proposed Sale	2.76	52,624	145,242		Aug 09 05:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XGN

Exagen Inc

Upgrade your FINVIZ experience